Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-36.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.68 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -92.51% |
| Return on Assets (Trailing 12 Months) | -38.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.01 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 59.88M |
| Free Float | 52.52M |
| Market Capitalization | $134.73M |
| Average Volume (Last 20 Days) | 3.51M |
| Beta (Past 60 Months) | 0.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 56.77% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |